Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00518206
Registration number
NCT00518206
Ethics application status
Date submitted
16/08/2007
Date registered
20/08/2007
Date last updated
25/10/2022
Titles & IDs
Public title
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
Query!
Scientific title
A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM® Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma
Query!
Secondary ID [1]
0
0
CTN Trial No.: 2007/123
Query!
Secondary ID [2]
0
0
LUD2002-013
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - NY-ESO-1 ISCOMATRIX® vaccine
Treatment: Drugs - Cyclophosphamide
Experimental: Cohort 1 - NY-ESO-1 ISCOM vaccine (100 µg of the NY-ESO-1 protein formulated with 120 µg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Experimental: Cohort 2 - Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 µg of the NY-ESO-1 protein formulated with 120 µg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Other interventions: NY-ESO-1 ISCOMATRIX® vaccine
NY-ESO-1 ISCOM vaccine (100 µg of the NY-ESO-1 protein formulated with 120 µg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Treatment: Drugs: Cyclophosphamide
Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 µg of the NY-ESO-1 protein formulated with 120 µg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Subjects With Best Overall Tumor Response
Query!
Assessment method [1]
0
0
Tumor responses were evaluated using computed tomography and categorized according to RECIST (version 1.0) at baseline, at week 11, between weeks 23 and 25, and every 12 weeks thereafter. Per RECIST, target lesions are categorized as follows: Complete Response (CR): Disappearance of all target lesions [no evidence of disease]; Partial Response (PR): = 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD): = 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria.
Query!
Timepoint [1]
0
0
Up to 22 months
Query!
Secondary outcome [1]
0
0
Cellular Immunogenicity of the NY-ESO-1 ISCOM Vaccine
Query!
Assessment method [1]
0
0
Blood samples were drawn to measure cellular response at pretreatment and weeks 3, 7, 11, between weeks 23 and 25, week 33, and every 12 weeks thereafter. Cellular immunity included an assay for gamma interferon-producing T cells and enumeration of NY-ESO-1b-specific T cells, detected by fluorescent labeled human leukocyte antigen (HLA)-A2 tetramers carrying the NY-ESO-1b peptide, expressed as percent positive staining of CD4+ and CD8+ T cells. Data are presented for CD4+ and CD8+ T-cell responses (not mutually exclusive) that were pre-existing at baseline (BL) or presented at any time post-BL.
Query!
Timepoint [1]
0
0
Up to 22 months
Query!
Secondary outcome [2]
0
0
Post-Vaccination Delayed-type Hypersensitivity (DTH) Reactions
Query!
Assessment method [2]
0
0
NY-ESO-1-specific DTH was measured by intradermal injection with the full-length NY-ESO-1 protein, NY-ESO-1b peptide, and NY-ESO-1 DP4 peptide at pretreatment, week 11, and between week 23 and 25. DTH reactions (eg, local skin irritation) were evaluated 2 days after DTH injections. Data presented are based on injections with the full-length peptide, as these data are considered to be representative of the comprehensive DTH results.
Query!
Timepoint [2]
0
0
Up to 22 months
Query!
Secondary outcome [3]
0
0
Humoral Immunogenicity of the NY-ESO-1 ISCOM Vaccine
Query!
Assessment method [3]
0
0
Blood samples were drawn to measure humoral immunologic response at pretreatment and weeks 3, 7, 11, 33, and every 12 weeks thereafter. Humoral immunity was assessed by measurement of antibodies to NY-ESO-1 by enzyme-linked immunosorbent assay (ELISA). Data are presented according to baseline (BL) NY-ESO-1 antibody positivity and the time to seroconversion, if applicable.
Query!
Timepoint [3]
0
0
Up to 22 months
Query!
Secondary outcome [4]
0
0
Number of Subjects With Treatment-emergent Adverse Events
Query!
Assessment method [4]
0
0
Toxicity was graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Treatment-emergent adverse events (TEAEs) were reported based on clinical laboratory tests, physical examinations, and vital signs from pre-treatment through the study period. Dose-limiting toxicity was defined as any treatment-related grade 4 toxicity or any grade 3 toxicity, excluding grade 3 skin necrosis at the site of the delayed-type hypersensitivity reaction, fever, or asymptomatic hyperglycemia that improved to baseline within 3 weeks of onset.
Query!
Timepoint [4]
0
0
Up to 22 months
Query!
Eligibility
Key inclusion criteria
1. Stage IV (metastatic) or unresectable stage III malignant melanoma.
2. Measurable disease using RECIST.
3. No other effective therapy available or appropriate.
4. Expression of NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) or reverse
transcription-polymerase chain reaction (RT-PCR).
5. Expected survival of at least 4 months.
6. Karnofsky performance status of = 70%.
7. Within 3 weeks prior to first administration of study drug, the following laboratory
parameters were required to be within the ranges specified:
- Hemoglobin = 100 g/L
- Platelets = 100 x 10^9/L
- International normalized ratio = 2.0
- Creatinine = 0.2 mmol/L
- Bilirubin = 30 mmol/L
8. Age = 18 years.
9. Able and willing to give written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding
disorders, or any condition that in the opinion of the Investigator would have
interfered with the ability of the patient to complete all study requirements.
2. Other malignancy within last 3 years, except for treated melanoma or non-melanoma skin
cancer or cervical cancer in situ.
3. Known immunodeficiency.
4. Known human immunodeficiency virus positivity.
5. Concomitant systemic treatment with corticosteroids, anti-histaminic drugs, or
nonsteroidal anti-inflammatory drugs. Specific cyclooxygenase-2 (COX-2) inhibitors,
low-dose aspirin for the prevention of an acute cardiovascular event, and topical or
inhaled steroids were permitted.
6. Chemotherapy and/or radiotherapy within 4 weeks prior to study week 1.
7. Other immunotherapy within 4 weeks prior to study week 1.
8. Mental impairment that may have compromised the ability to give informed consent and
comply with the requirements of the study.
9. Lack of availability for immunological and clinical follow-up assessment.
10. Participation in any other clinical trial involving another investigational agent
within 4 weeks prior to enrollment.
11. Pregnancy or breastfeeding.
12. Women of childbearing potential: refusal or inability to use effective means of
contraception.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/11/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/01/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
46
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Peter MacCallum Cancer Institute - East Melbourne
Query!
Recruitment hospital [2]
0
0
Austin Health (Ludwig Institute Oncology Unit) - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3084 - Heidelberg
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Ludwig Institute for Cancer Research
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Austin Health
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Peter MacCallum Cancer Institute
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a Phase 2, open-label study of the NY-ESO-1 ISCOMATRIX® (ISCOM) vaccine administered
as an intramuscular injection given every 4 weeks to subjects with measurable advanced
malignant melanoma. Study objectives included determination of the anticancer activity,
cellular and humoral immunogenicity, and safety and tolerability of the NY-ESO-1 ISCOM
vaccine administered alone or preceded by a single administration of low-dose
cyclophosphamide.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00518206
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jonathan S Cebon, FRACP, MBBS, PhD
Query!
Address
0
0
Ludwig Institute for Cancer Research - Oncology Unit
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00518206
Download to PDF